Oxford, UK – August 9, 2018 – Blue Earth Diagnostics, a leading molecular imaging diagnostics company, yesterday announced that it has been shortlisted as a finalist in the 2018 OBN awards in the category “Best Emerging Biotech Company”. These prestigious awards, which are judged by a panel of leading industry entrepreneurs and experts, celebrate innovation and outstanding achievement across the UK’s Life Sciences industry.
The first half of 2018 has delivered several pivotal developments for the advanced therapies industry. The year began with two significant acquisitions – in January Celgene acquired Juno for $9bn and Sanofi acquired Bioverativ for $11.5bn - and the EMA recently approved the first two CAR-T cell medicines – Novartis’ Kymriah and Kite’s Yescarta. This follows a bumper year for the sector in 2017, in which Kymriah and Yescarta both received FDA approval and Gilead acquired Kite for $11.9bn. So how long will this trend continue? How can the advanced therapies industry maintain and build on this momentum and does the industry need to adapt and evolve to ensure sustainable success?
Synthace Ltd., the company behind the leading cloud software platform for automating and improving the success rate of biological research and development today announced the appointment of Susan Shiff Ph.D., MBA, to its board of directors.
Norwich, UK: Leaf Expression Systems, a contract development business specialising in plant expression of proteins, metabolites and complex natural products, announced today that life sciences veteran Simon J.Y Saxby has joined the company as CEO. The appointment comes as Leaf Expression System’s multi-million pound purpose-built facility on the Norwich Research Park becomes fully operational amidst growing interest worldwide in its game-changing plant expression technology, Hypertrans®.
As we communicated in last week’s Newscast, the government has published guidance documents which offer a certain amount of clarity on how life sciences companies will be able to operate during an implementation period. I’d encourage you to look at these if you have not already done so. BIA Member Cancer Research UK has also published a policy statement on the future of clinical trials as the UK leaves the EU, which gives an insight into just some of the concerns delays at the borders may cause. Clinical trials to treat neuroblastoma, a rare and aggressive cancer most often affecting babies and children, involve the use of iodine-124, a radioactive material.
Louise Brown was a miracle baby like no other - the first baby born using IVF. She was born on 25 July 1978, having been conceived using a technique devised by British researchers Robert Edwards, Patrick Steptoe and Jean Purdy. 40 years after her birth, and 6 million IVF babies later, this technology continues to bring hope and happiness to many couples.
Cambridge, UK., 9th August 2018: Arecor Ltd (“the Company”), the UK-based leading formulation technology company, focused on developing superior biopharmaceuticals via the innovative reformulation of proteins and peptides, is pleased to announce its participation at the Bioprocessing Summit, 13th-17th August 2018, at the Sheraton Boston Hotel, Boston, Massachusetts, USA.
On Thursday 12 July, the same day the government published its Brexit White Paper, more than 35 senior representatives from UK life sciences companies convened in London for the BIA’s annual Parliament Day. As our flagship influencing event, Parliament Day facilitates important interactions between BIA members and policymakers across Westminster and Whitehall.
This is the latest update from the Medicines Manufacturing Industry Partnership capturing the key highlights from the first six busy months of this year. If you have any feedback on the content or information here then please email us at MMIP@bioindustry.org. If you have any colleagues you feel would be interested in learning more about the work of MMIP then please ask them to get in touch with us or sign up to our mailing list here.
Welcome to the first Life Sciences Industrial Strategy & Sector Deal Newsletter. Here you will find an update on how we are progressing with the implementation of phase 1 of the Life Sciences Sector Deal as well as our upcoming priorities and engagement opportunities.